设为首页 电子邮箱 联系我们

本刊最新招聘信息请见“通知公告”!  本刊投稿系统试运行中,欢迎投稿!如投稿有问题,可直接将稿件发送至zgyy8888@163.com

 

主管单位:中华人民共和国   

国家卫生健康委员会

主办单位:中国医师协会
总编辑:
杨秋

副总编辑:魏永祥、张运、

罗毅、谭学瑞、唐来坤、

王喜艳

编辑部主任:杨秋

邮发代号:80-528
定价:20.00元
全年:240.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)

                  

过刊目录

2021 年第 9 期 第 16 卷

吡嗪酰胺片高脂餐后服用在健康受试者中的生物等效性和安全性

Bioequivalence and safety of pyrazinamide tablets after high-fat meal in healthy subjects

作者:荆珊刘文芳李静赵桂平谭莉杨克旭所伟鲁春艳林阳

英文作者:Jing Shan Liu Wenfang Li Jing Zhao Guiping Tan Li Yang Kexu Suo Wei Lu Chunyan Lin Yang

单位:首都医科大学附属北京安贞医院临床药理中心100029

英文单位:Clinical Pharmacology Centre Beijing Anzhen Hospital Capital Medical University Beijing 100029 China

关键词:生物等效性;临床试验;吡嗪酰胺;高脂餐;健康受试者;临床用药;安全性

英文关键词:Bioequivalence;Clinicaltrial;Pyrazinamide;High-fatmeal;Healthysubjects;Chinicalmedication;Safety

  • 摘要:
  • 目的 评价健康受试者高脂餐后口服吡嗪酰胺片的生物等效性和安全性。方法 采用单中心、随机、开放、两周期、双交叉设计的生物等效性研究,将受试者随机分为受试制剂-参比制剂组和参比制剂-受试制剂组,受试制剂为太仓制药厂生产的吡嗪酰胺片;参比制剂为美国ULTRAtab Laboratories, Inc.生产的Pyrazinamide,分别在第1天和第8天高脂餐后接受1次受试制剂和1次参比制剂500 mg,比较2种制剂的生物等效性。周期之间的洗脱期为7 d。按方案规定的时间点采集生物样本进行血药浓度的分析,对吡嗪酰胺的主要药代动力学参数血药峰浓度(Cmax)、从0时至t时血药浓度-时间曲线下面积(AUC0~t)和0时至无穷大的血药浓度-时间曲线下面积(AUCinf)进行等效性评价。结果 24名受试者纳入研究,包括男16名(66.7%)、女8名(33.3%),年龄(35±9)岁。24名均完成2次给药及随访。生物等效性研究结果显示,2种吡嗪酰胺片高脂餐后试验,主要药代动力学参数CmaxAUC0~tAUCinf的几何均数比值分别为97.00%98.80%98.70%90%置信区间分别为92.91%101.27%96.52%101.13%96.35%101.11%,均落在常规生物等效80.00%125.00%范围内。研究期间2组受试者均未发生导致退出研究的不良事件和严重不良事件。结论 2种吡嗪酰胺片制剂在高脂餐后的健康受试者中具有生物等效性,安全性良好。

  • Objective To evaluate the bioequivalence and safety of pyrazinamide tablets orally after eating high-fat meal in healthy subjects. Methods A single-center, randomized, open, two-period, and two-crossover design bioequivalence study was performed. Subjects were randomly divided into test-reference preparations group and reference-test preparations group. The test preparation was pyrazinamide tablets produced by Taicang Pharmaceutical Factory; the reference preparation Pyrazinamide was produced by ULTRAtab Laboratories, Inc., America. Subjects in the two groups were given the test preparation or the reference preparation 500 mg after high-fat meal on the 1st and 8th day, respectively. The bioequivalence of the two preparations was compared. The washout period between cycles was 7 d. Biological samples were collected at the protocol scheduled time points for blood concentration analysis. The equivalence of the main pharmacokinetic parameters of pyrazinamide was evaluated: peak blood concentration(Cmax), the area under the curve from time 0 to t (AUC0-t) and the area under the curve from time 0 to infinity(AUCinf). Results Twenty-four subjects were included in this study, including 16 males(66.7%) and 8 females(33.3%), aged (35±9)years. All subjects completed 2 times of drug administration and follow-up. The results of bioequivalence study showed that the geometric mean ratios of main pharmacokinetic parameters Cmax, AUC0-t and AUCinf of the two pyrazinamide tablets were 97.00%, 98.80% and 98.70%, and 90% confidence interval were 92.91%-101.27%, 96.52%-101.13% and 96.35%-101.11%, respectively, within the regular bioequivalence range 80.00%-125.00%. During the study period, there were no adverse events leading subjects withdrawal or serious adverse events in both groups. Conclusion The two pyrazinamide tablets preparations are bioequivalent in healthy subjects after high-fat meal and have good safety.

copyright 《中国医药》杂志编辑部
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址:www.chinamedicinej.com 京ICP备2020043099号-3
本系统由北京博思汇文数字科技有限公司设计开发 技术服务电话:400-921-9838
当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。







安卓


苹果

关闭